General Information of Drug (ID: DMNZKCL)

Drug Name
N,N`-bis-alkyl butylimmidazole 12b Drug Info
Synonyms compound 12b [PMID: 23376252]
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
73755247
TTD Drug ID
DMNZKCL

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Losartan DM72JXH Diabetic kidney disease GB61.Z Approved [2]
Olmesartan medoxomil DMWBHRY High blood pressure BA00 Approved [3]
Irbesartan DMTP1DC Diabetic kidney disease GB61.Z Approved [2]
Valsartan DMREUQ6 Chronic heart failure BD1Z Approved [2]
Candesartan DMRK8OT Chronic heart failure BD1Z Approved [4]
Telmisartan DMS3GX2 Hypertension BA00-BA04 Approved [5]
ANGIOTENSIN II DMLWQ27 Increase blood pressure BA04 Approved [6]
SARALASIN DMKS1DV Hypertension BA00-BA04 Approved [7]
Tasosartan DMM13DI Hypertension BA00-BA04 Approved [8]
Eprosartan DM07K2I Hypertension BA00-BA04 Approved [9]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Angiotensin II receptor type-1 (AGTR1) TT8DBY3 AGTR1_HUMAN Antagonist [1]

References

1 Rational design, efficient syntheses and biological evaluation of N,N'-symmetrically bis-substituted butylimidazole analogs as a new class of potent Angiotensin II receptor blockers. Eur J Med Chem. 2013 Apr;62:352-70.
2 Radioligand binding assays: application of [(125)I]angiotensin II receptor binding. Methods Mol Biol. 2009;552:131-41.
3 Mechanism of diastolic stiffening of the failing myocardium and its prevention by angiotensin receptor and calcium channel blockers. J Cardiovasc Pharmacol. 2009 Jul;54(1):47-56.
4 Candesartan: widening indications for this angiotensin II receptor blocker Expert Opin Pharmacother. 2009 Aug;10(12):1995-2007.
5 Deletion of angiotensin II type I receptor reduces hepatic steatosis. J Hepatol. 2009 Jun;50(6):1226-35.
6 The amino-terminus of angiotensin II contacts several ectodomains of the angiotensin II receptor AT1. J Med Chem. 2010 Mar 11;53(5):2063-75.
7 Identification of a potent, selective, and orally active leukotriene a4 hydrolase inhibitor with anti-inflammatory activity. J Med Chem. 2008 Jul 24;51(14):4150-69.
8 Tasosartan, enoltasosartan, and angiotensin II receptor blockade: the confounding role of protein binding. J Pharmacol Exp Ther. 2000 Nov;295(2):649-54.
9 Clinical profile of eprosartan: a different angiotensin II receptor blocker. Cardiovasc Hematol Agents Med Chem. 2008 Oct;6(4):253-7.